Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 124

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 124
---
astem 
  Ordinary Share 
         closing 
 price per share 
          ($)(1) |     |         Market 
 capitalization 
         of NLS 
   Common Share |     |         Market 
 capitalization 
  of Kadimastem 
 Ordinary Share |     |        Equivalent 
   value of Merger 
 consideration per 
        Kadimastem 
          Ordinary 
          Share(2) |
| July 29, 2024 |     |          9.35 |     |            1.59 |     |     31,040,091 |     |      6,661,646 |     |        12,321,983 |
| July 9, 2025  |     |          2.28 |     |            7.31 |     |      9,446,617 |     |     32,983,874 |     |        53,313,340 |

____________ (1)As Kadimastem Ordinary Shares trade on the TASE, there is a lack of liquidity. It is therefore difficult to determine a current active market valuation. Prior to the announcement of the deal, daily trading volume was around $1,500. (2)In accordance with the Merger Agreement on a fully diluted basis. Represents the total value of Kadimastem Ordinary Shares to be exchanged for NLS Common Shares as part of the Merger. (3)Moore’s valuation report for Kadimastem attached to this proxy statement/prospectus values it at $71,307,000 based on the details analysis. The market prices of NLS Common Share and Kadimastem Ordinary Share have fluctuated since the date of the announcement of the Merger Agreement and will continue to fluctuate from the date of this proxy statement/prospectus to the date of the NLS Meeting and the date the Merger is completed and thereafter. See “ Risk Factors — Risks Related to the Merger” in this proxy statement/prospectus. We encourage you to obtain current quotes for the NLS Common Share and Kadimastem Ordinary Share.

22 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain statements in this proxy statement/prospectus may constitute “forward -lookingstatements” for purposes of the federal securities laws. Forward -lookingstatements include, but are not limited to, statements regarding NLS, Kadimastem and their respective management teams’ expectations, hopes, beliefs, intentions or strategies regarding the future. In